BioCentury
ARTICLE | Top Story

Regeneron's anti-NGF mAb meets Phase II/III endpoint

May 3, 2016 1:35 AM UTC

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said fasinumab ( REGN475) met the primary endpoint of significantly improving pain relief vs. placebo in a Phase II/III study to treat moderate to severe osteoarthritis (OA) pain of the hip or knee. Patients receiving 1 mg, 3 mg, 6 mg or 9 mg of the mAb against nerve growth factor every four weeks through week 12 improved WOMAC pain subscale scores from baseline to week 16 by 3.35, 3.33, 3.03 and 3.65 points vs. 2.25 for placebo (p=0.0025, p=0.0029, p=0.0304 and p=0.0001).

The study enrolled 421 patients with a history of inadequate pain relief or intolerance to current analgesic therapies. Patients had an average pain score of 6.3 points at baseline. ...